Dimensional Fund Advisors LP Sells 11,190 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

Dimensional Fund Advisors LP decreased its holdings in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) by 32.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 23,033 shares of the company’s stock after selling 11,190 shares during the period. Dimensional Fund Advisors LP’s holdings in Eledon Pharmaceuticals were worth $95,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ELDN. Kera Capital Partners Inc. bought a new position in shares of Eledon Pharmaceuticals during the 4th quarter valued at about $106,000. Inspire Investing LLC purchased a new stake in Eledon Pharmaceuticals in the 4th quarter worth approximately $802,000. Charles Schwab Investment Management Inc. lifted its holdings in Eledon Pharmaceuticals by 100.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 29,987 shares of the company’s stock worth $124,000 after buying an additional 15,000 shares during the period. Virtu Financial LLC purchased a new position in shares of Eledon Pharmaceuticals in the 4th quarter valued at approximately $82,000. Finally, Geode Capital Management LLC lifted its stake in shares of Eledon Pharmaceuticals by 75.4% in the 4th quarter. Geode Capital Management LLC now owns 663,101 shares of the company’s stock valued at $2,733,000 after purchasing an additional 285,043 shares during the period. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

Eledon Pharmaceuticals Price Performance

Shares of ELDN stock opened at $2.87 on Friday. The company has a market capitalization of $171.86 million, a price-to-earnings ratio of -1.43 and a beta of 0.08. Eledon Pharmaceuticals, Inc. has a one year low of $2.30 and a one year high of $5.54. The company’s fifty day moving average price is $3.17 and its 200-day moving average price is $3.95.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.20. Equities research analysts expect that Eledon Pharmaceuticals, Inc. will post -0.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Guggenheim assumed coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a “buy” rating and a $9.00 price objective for the company.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).